A phase Ib clinical trial suggests that administering a concentrated dose of anti-CEA CAR-T cells precisely at the site of a solid tumor by means of TriSalus Life Sciences’ unique Pressure-enabled Drug Delivery is safe, with encouraging clinical responses.
When The Cancer Letter founder Jerry Boyd carried the first print run of his little eight page oncology newsletter into an NCAB meeting in 1973, he certainly could not have predicted that, half a century later, his experiment would branch out into this thing called “podcasts.”
